Iqvia Holdings Inc.IQV

IQVIA HOLDINGS INC. just filed its 10-Q for the quarter ended 31 March 2026, and the numbers tell a story the glossy AI keynotes don’t: $4.15 billion in revenue, $274 million in net income, $514 million in operating income, and $618 million in net cash from operations. Diluted EPS clocked in at $1.61 on 169.8 million shares. Assets stood at $29.68 billion, liabilities at $23.33 billion, and equity at $6.22 billion, with $1.95 billion in cash and equivalents sitting pretty on the balance sheet. The filings are filed; the cash is collected; the optics are intact. (source: SEC EDGAR 10-Q for IQVIA HOLDINGS INC., period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1478242/000162828026048761/xslF345X06/wk-form10q_1784235959.xml)

IQVIA’s public identity is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, a positioning it reiterates in press releases and product pages. The marquee launch of AI agents at GTC Paris in June 2025 sits alongside a Clinical Trial Financial Suite that unifies budgeting, contracting, forecasting, and payments in a single agentic AI-powered platform. Functional services, patient & site-centric solutions, and Phase IIb/III trial offerings round out a portfolio aimed squarely at sponsors who need clinical trials run at scale without the spreadsheet sprawl. (source: IQVIA newsroom and product pages, https://www.iqvia.com/newsroom/2025/06/iqvia-launches-new-ai-agents-for-life-sciences-and-healthcare, https://www.iqvia.com/solutions/technologies/clinical-trial-financial-suite, https://www.iqvia.com/solutions/research-and-development/functional-services, https://www.iqvia.com/solutions/research-and-development/patient-and-site-centric-solutions, https://www.iqvia.com/solutions/research-and-development/phase-iibiii-trials)

The filings show the machine but not the motive. Despite the product fanfare, the 10-Q does not break out revenue by segment, disclose customer concentration, or quantify contract renewal rates. Management commentary is absent from the filing, leaving investors to infer performance from broad metrics rather than granular disclosures. The board’s July 2026 Form 4 cluster-four identical filings on the same day-projects an orderly narrative, yet provides zero context about the trades themselves. That’s not illegal; it’s just thin. (source: SEC EDGAR 10-Q and Form 4 index, https://www.sec.gov/Archives/edgar/data/1478242/000162828026048761/xslF345X06/wk-form10q_1784235959.xml, https://www.sec.gov/Archives/edgar/browse/?CIK=1478242)

The company’s investor-relations page points to an SEC submissions JSON and company facts JSON, both of which are raw data dumps rather than narrative aids. The submissions feed lists 8-Ks from 4 June 2026 and 11 June 2026, but the filings themselves are boilerplate disclosures-no new contracts, no restatements, no material restatements of guidance. The JSON is a filing index, not a story. (source: SEC submissions JSON and company facts JSON, https://data.sec.gov/submissions/CIK0001478242.json, https://data.sec.gov/api/xbrl/companyfacts/CIK0001478242.json)

If you’re hunting for market levels, IQVIA trades on the NYSE under ticker IQV, and the official route for charting is the exchange’s live feed. TradingView provides the venue, but the file offers no levels, ranges, or commentary on liquidity-because none are supplied in the evidence. The chart is the chart; the story is the spreadsheets. (source: NYSE market data route, https://www.nyse.com/quote/XNYS:IQV)

The file is thin on what matters next: revenue growth by segment, customer retention, pricing power on the Clinical Trial Financial Suite, and any EBITDA bridge that maps AI investment to margin. Until those disclosures arrive, the cleanest read is that IQVIA is a cash-generative clinical trial factory with a marketing team that prefers the future tense. The filings are real; the upside claims are promotional. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1478242/000162828026048761/xslF345X06/wk-form10q_1784235959.xml)